Comparative Pharmacology
Head-to-head clinical analysis: ASACOL HD versus BALSALAZIDE DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL HD versus BALSALAZIDE DISODIUM.
ASACOL HD vs BALSALAZIDE DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
Prodrug that delivers mesalamine (5-aminosalicylic acid) to the colon; mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, and scavenges reactive oxygen species, thereby decreasing colonic inflammation.
2 tablets (1600 mg) once daily with or without food.
2.25 g (three 750 mg capsules) orally three times daily
None Documented
None Documented
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Balsalazide itself has a terminal elimination half-life of approximately 0.5–1 hour; the active moiety mesalamine has a terminal half-life of 5–10 hours, which may be prolonged in renal impairment.
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Primarily excreted in feces via biliary elimination (approximately 90%) following conversion to mesalamine; renal excretion accounts for less than 10% of the dose as mesalamine and its metabolites.
Category C
Category C
Aminosalicylate
Aminosalicylate